A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity (Q43722893)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 June 2009

Language	Label	Description	Also known as
English	A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity	scientific article published on 17 June 2009

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity (English)

1 reference

Europe PubMed Central

26 November 2017

0 references

Jason Kindrachuk

1

object named as

Jason Kindrachuk

0 references

Scott A Halperin

9

object named as

Scott A Halperin

1 reference

Europe PubMed Central

26 November 2017

Robert E. W. Hancock

10

object named as

Robert E W Hancock

1 reference

Europe PubMed Central

26 November 2017

7

object named as

Volker Gerdts

1 reference

Europe PubMed Central

26 November 2017

8

object named as

Lorne A Babiuk

1 reference

Europe PubMed Central

26 November 2017

author name string

Jason Kindrachuk

1

1 reference

Europe PubMed Central

26 November 2017

Håvard Jenssen

2

1 reference

Europe PubMed Central

26 November 2017

Melissa Elliott

3

1 reference

Europe PubMed Central

26 November 2017

Rebecca Townsend

4

1 reference

Europe PubMed Central

26 November 2017

Anastasia Nijnik

5

1 reference

Europe PubMed Central

26 November 2017

Song F Lee

6

1 reference

Europe PubMed Central

26 November 2017

language of work or name

0 references

publication date

17 June 2009

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

27

1 reference

Europe PubMed Central

26 November 2017

4662-4671

1 reference

Europe PubMed Central

26 November 2017

34

1 reference

Europe PubMed Central

26 November 2017

Strategies to link innate and adaptive immunity when designing vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Vaccine adjuvants revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Immunomodulatory activities of small host defense peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Neutrophil-derived defensins as modulators of innate immune function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

beta-Defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Monocyte-chemotactic activity of defensins from human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Mechanisms for induction of acquired host immunity by neutrophil peptide defensins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

An anti-infective peptide that selectively modulates the innate immune response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Antibody repertoire development in fetal and neonatal piglets. IX. Three pathogen-associated molecular patterns act synergistically to allow germfree piglets to respond to type 2 thymus-independent and thymus-dependent antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Co-administration of porcine-specific CpG oligodeoxynucleotide enhances the immune responses to pseudorabies attenuated virus vaccine in newborn piglets in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Role of D-alanylation of Streptococcus gordonii lipoteichoic acid in innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A2-ROS signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Mechanisms of antimicrobial peptide action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Differential effects of alpha- and beta-defensin on cytokine production by cultured human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Host defense peptides in wound healing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Separation and quantification of a novel two-component vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.094

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.05.094

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43722893&oldid=2102841188"